Jazz Pharmaceuticals plc provided earnings guidance for the full year 2024. For the period, the company expected revenues to be in the range of $4,000 million to $4,200 million, net income of $385 million to $530 million and net income per diluted share to be in the range of $5.80 to $7.70.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
113.1 USD | +3.18% | +2.94% | -8.06% |
07:10pm | US reclassification could drive fresh research funding into pot sector | RE |
05-07 | Jazz Pharmaceuticals Insider Sold Shares Worth $548,250, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.06% | 6.91B | |
+30.02% | 684B | |
+30.34% | 568B | |
-3.84% | 361B | |
+18.11% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.12% | 166B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024